A 42-year-old man with moderate persistent asthma has been on inhaled beclomethasone dipropionate (BDP) 250 µg twice daily for 8 months. He is now referred to the endocrinology clinic for evaluation of hypogonadism (low testosterone, elevated LH). His morning cortisol is 8 µg/dL (normal 10–20 µg/dL) and ACTH is 35 pg/mL (normal 10–50 pg/mL). Bone mineral density (BMD) T-score is −1.8 at the lumbar spine. What is the most likely explanation for these findings?

Explanation

## Clinical Presentation Analysis The patient presents with a constellation of findings consistent with **systemic corticosteroid toxicity from chronic high-dose inhaled corticosteroids (ICS)**: - Low morning cortisol (8 µg/dL, normal >10 µg/dL) - Elevated LH with hypogonadism (secondary hypogonadism) - Reduced bone mineral density (T-score −1.8 = osteopenia) - 8 months of high-dose BDP (250 µg × 2 = 500 µg/day) ## Mechanism of Systemic ICS Absorption **Key Point:** Although ICS are designed for local lung deposition, systemic absorption occurs via two routes: 1. **Lung absorption** (~20–25% of inhaled dose) → hepatic first-pass metabolism → active metabolites 2. **Oropharyngeal swallowing** (~75–80% of dose) → GI absorption → hepatic metabolism BDP is a **prodrug** that undergoes hepatic esterification to **beclomethasone-17-monopropionate (BMP)**, the active metabolite. Even though BDP has high first-pass metabolism, chronic high-dose therapy allows sufficient systemic corticosteroid exposure to suppress the HPA axis. ## HPA Axis Suppression Cascade ```mermaid flowchart TD A[Chronic high-dose ICS]:::action --> B[Systemic corticosteroid accumulation]:::outcome B --> C[Negative feedback on hypothalamus/pituitary]:::action C --> D[↓ CRH and ACTH secretion]:::outcome D --> E[↓ Cortisol production]:::outcome E --> F[Secondary adrenal insufficiency]:::urgent F --> G[↓ DHEA-S and testosterone]:::outcome G --> H[Secondary hypogonadism]:::outcome B --> I[↓ Bone turnover + ↑ bone resorption]:::action I --> J[Osteopenia/Osteoporosis]:::outcome ``` ## Interpretation of Cortisol & ACTH | Parameter | Value | Normal | Interpretation | |-----------|-------|--------|----------------| | Morning cortisol | 8 µg/dL | 10–20 µg/dL | **Low** (suppressed) | | ACTH | 35 pg/mL | 10–50 pg/mL | **Normal-to-low** (inappropriately low for low cortisol) | | **Diagnosis** | — | — | **Secondary adrenal insufficiency** (HPA axis suppression) | **Clinical Pearl:** In secondary adrenal insufficiency from ICS, ACTH is typically low-normal or frankly low because the pituitary is suppressed. This distinguishes it from primary adrenal insufficiency (where ACTH would be markedly elevated). ## Hypogonadism Mechanism Chronic corticosteroid excess suppresses **GnRH secretion** from the hypothalamus, leading to: - ↓ LH and FSH - ↓ Testosterone production (secondary hypogonadism) - Elevated LH (as seen here) suggests partial pituitary suppression with some compensatory response ## Osteopenia Pathophysiology **High-Yield:** Corticosteroids cause bone loss via: 1. ↓ Osteoblast function and bone formation 2. ↑ Osteoclast activity and bone resorption 3. ↓ Calcium absorption in gut 4. ↑ Urinary calcium wasting 5. ↓ Sex hormone production (further bone loss) T-score −1.8 indicates osteopenia; risk of fracture increases significantly. ## Risk Factors for Systemic ICS Absorption | Factor | Impact | |--------|--------| | **High ICS dose** (>400 µg/day) | ↑↑ Systemic absorption | | **Duration of therapy** (>3 months) | Cumulative effect | | **Poor inhaler technique** | ↑ Oropharyngeal deposition | | **Use of spacer** | ↓ Systemic absorption | | **ICS type** (BDP > fluticasone) | BDP has lower first-pass metabolism | | **Age & BMI** | May affect metabolism | ## Management of HPA Axis Suppression 1. **Reduce ICS dose** to the minimum effective dose (target <400 µg/day BDP equivalent) 2. **Optimize inhaler technique** and use spacer to reduce systemic absorption 3. **Monitor HPA axis recovery** with repeat morning cortisol after 4–8 weeks 4. **Consider DEXA scan** and osteoporosis prophylaxis (calcium, vitamin D, bisphosphonate if needed) 5. **Assess testosterone** and consider HRT if hypogonadism persists after ICS reduction 6. **Educate patient** on mouth rinsing and spacer use to reduce oropharyngeal swallowing **Mnemonic:** **CRASH** — Corticosteroid suppression, Reduce ICS dose, Assess HPA axis, Spacer use, Handle osteopenia. [cite:KD Tripathi 8e Ch 28; Harrison 21e Ch 305]